Christopher J.  Scoggins net worth and biography

Christopher Scoggins Biography and Net Worth

Christopher J. Scoggins serves as Senior Vice President - Rapid Diagnostics of the Company. He serve as Vice President, Diabetes Care, Commercial Operations from 2015-2019. Divisional Vice President, EMEA Commercial Operations, ADC. from 2011-2015.

What is Christopher J. Scoggins' net worth?

The estimated net worth of Christopher J. Scoggins is at least $4.51 million as of April 21st, 2020. Scoggins owns 39,706 shares of Abbott Laboratories stock worth more than $4,505,837 as of March 28th. This net worth approximation does not reflect any other investments that Scoggins may own. Learn More about Christopher J. Scoggins' net worth.

How old is Christopher J. Scoggins?

Scoggins is currently 54 years old. There are 7 older executives and no younger executives at Abbott Laboratories. The oldest executive at Abbott Laboratories is Mr. Robert E. Funck Jr., Executive Vice President of Finance, who is 63 years old. Learn More on Christopher J. Scoggins' age.

How do I contact Christopher J. Scoggins?

The corporate mailing address for Scoggins and other Abbott Laboratories executives is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. Abbott Laboratories can also be reached via phone at (224) 667-6100. Learn More on Christopher J. Scoggins' contact information.

Has Christopher J. Scoggins been buying or selling shares of Abbott Laboratories?

Christopher J. Scoggins has not been actively trading shares of Abbott Laboratories over the course of the past ninety days. Most recently, Christopher J. Scoggins sold 414 shares of the business's stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $96.10, for a transaction totalling $39,785.40. Following the completion of the sale, the senior vice president now directly owns 39,706 shares of the company's stock, valued at $3,815,746.60. Learn More on Christopher J. Scoggins' trading history.

Who are Abbott Laboratories' active insiders?

Abbott Laboratories' insider roster includes Hubert Allen (Insider), Roxanne Austin (Director), Roger Bird (SVP), Brian Blaser (Insider), Philip Boudreau (VP), Sharon Bracken (Insider), John Capek (EVP), Jaime Contreras (SVP), Michael Dale (SVP), Lisa Earnhardt (EVP), Robert Ford (Chairman), Robert Ford (CEO), Robert Funck (CFO), Stephen Fussell (EVP), John Ginascol (EVP), Sammy Karam (SVP), Michelle Kumbier (Director), Andrew Lane (EVP), Joseph Manning (SVP), Nancy Mckinstry (Director), Mary Moreland (EVP), Louis Morrone (SVP), Phebe Novakovic (Director), Michael Pederson (SVP), Daniel Salvadori (EVP), Christopher Scoggins (SVP), Daniel Starks (Director), Julie Tyler (SVP), Andrea Wainer (EVP), Jared Watkin (SVP), Miles White (Chairman), Randel Woodgrift (SVP), and Brian Yoor (CFO). Learn More on Abbott Laboratories' active insiders.

Are insiders buying or selling shares of Abbott Laboratories?

During the last year, insiders at the healthcare product maker sold shares 10 times. They sold a total of 240,061 shares worth more than $26,014,576.06. The most recent insider tranaction occured on March, 1st when EVP Daniel Gesua Sive Salvadori sold 963 shares worth more than $114,115.50. Insiders at Abbott Laboratories own 1.1% of the company. Learn More about insider trades at Abbott Laboratories.

Information on this page was last updated on 3/1/2024.

Christopher J. Scoggins Insider Trading History at Abbott Laboratories

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/21/2020Sell414$96.10$39,785.4039,706View SEC Filing Icon  
See Full Table

Christopher J. Scoggins Buying and Selling Activity at Abbott Laboratories

This chart shows Christopher J Scoggins's buying and selling at Abbott Laboratories by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Abbott Laboratories Company Overview

Abbott Laboratories logo
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Read More

Today's Range

Now: $113.48
Low: $113.09
High: $113.94

50 Day Range

MA: $115.14
Low: $110.01
High: $120.98

2 Week Range

Now: $113.48
Low: $89.67
High: $121.64

Volume

658,976 shs

Average Volume

5,669,453 shs

Market Capitalization

$196.91 billion

P/E Ratio

34.81

Dividend Yield

1.97%

Beta

0.75